"The company''s core objective of enhancing shareholder
value achieved a significant milestone with Wockhardt''s
market capitalisation crossing the $1 billion mark on
the back of our sustained robust financial performance,"
announced Habil Khorakiwala, chairman of pharmaceutical
and biotechnology major Wockhardt Ltd, while presenting
the company''s Q2 2005 and half yearly consolidated results.
has reported a 55 per cent rise in net profit for the
second quarter ended June 30, 2005. Sales, at Rs377
crore, showed a 29 per cent increase over the corresponding
quarter of 2004.
profit increased by 39 per cent at Rs96 crore during
the quarter. Operating margins improved by 180 basis
points to 25.4 per cent.
year net profit amounted to Rs119 crore on sales of
the Wockhardt Biotech Park has also received the GMP
(good manufacturing practices) certification for its
Wepox facility from the World Health Organisation (WHO)
during the quarter.